Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Revolutionary Test Offers Cancer Pts. Chance to Improve Outcomes 200%

Newport Beach, California, United States - 09-01-2022 (PR Distribution™) -

Every living cell has an enemy – Superman had Kryptonite, Nightwalkers had Dragonglass, and cancer has chemotherapy when properly prescribed!

According to Gregory DiRienzo, CEO of Integrative Cancer Centers of America (www.iccahelp.com), chemotherapy known to kill one patient’s cancer, may very well not kill another's – even with an identical diagnosis! 

What's equally troubling according to DiRienzo, is that a 2019 study published in JAMA Internal Medicine states only 20% (19 of 93) of cancer chemo's fast-tracked through the U.S. FDA’s accelerated approval process, ever ending up extending the patient’s life. 

Moreover, with the hundreds of chemo's, chemo combinations, and/or targeting agents available on the marketplace, how an oncologist know which medicine will work best for treating that patient’s unique cancer cells?  

They probably won’t -- for most oncologists can only prescribe medicines that 1) approved through clinical trials, 2) have passed, often, overly restrictive NCCN guidelines, and/or 3) unavailable as an insurance reimbursable. 

Fortunately, ICCA’s medical team can select with great certainty, exactly which medicine will work best at killing that patient’s unique cancer cells, not someone else's!

The test will also reveal which medicine(s) or combination do not work for that patient’s unique cancer cells, thus reducing potential life-threatening treatment time, unnecessary treatment costs, and potentially damaging side effects. 

Regrettably, “average” treatments only produce “average” outcomes, with many, many patients often failing to show any favorable treatment outcomes when just “average” medicines are prescribed! 

Over 12,500 tumor profiles have been performed to date – with many studies showing a 200% higher response rate than patients who did not undergo the tumor profiling. 

This is a huge game changer for any cancer patient: 1) whose medicine has failed to work 2) wants to receive the best medicine the first time, and 3) greatly assist the oncologist in selecting the absolute best medicine available for that patient's particular cancer!

For Further Information: 

Gregory DiRienzo, CEO

Integrative Cancer Centers America 

(www.iccahelp.com

greg@iccahelp.com

001.888.526.6398 

Media Contacts:

Company Name: Integrative Cancer Centers of America
Full Name: Gregory DiRienzo
Phone: 9499390050
Email Address: Send Email
Website: http://www.iccahelp.com

For the original news story, please visit https://www.prdistribution.com/news/revolutionary-test-offers-cancer-pts-chance-to-improve-outcomes-200/9269454.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.